The ESC—the International Stroke Conference in Europe—developed since 1990 into the most important platform for exchanging the latest research results and innovations in the prevention and treatment of stroke. The aim is to combine existing knowledge with the development and implementation of improved concepts for the benefit of patients across Europe. Continuing this successful paths with you is the formulated wish of the ESC from 24–26 May 2017 in Berlin, Germany.
We aim to offer an open academic forum that will stimulate discussions on the latest scientific developments on stroke and associated diseases, e.g., neurodegeneration, neuroimmunological and oncological problems as well as age-related diseases. This will further generate new ideas in the field of basic and clinical cerebrovascular research and life-long learning and education.
The ESC programme committee is working very hard to achieve and surpass the academic standards that have been improved over the last 26 years. Participants from all around the globe (> 80 countries were represented 2015 in Vienna and 2016 in Venice) will have the opportunity to meet and interact with our partners in the Stroke Industry worldwide through exhibits and industry sessions. You will find your partners in clinical stroke management and translational research in Asia, Australia, America and Europe with us!
Join us at the 26th European Stroke Conference 2017 in the beautiful city of Berlin!
The scientific program of ICCAD 2017 is being planned with the collaboration and endorsement of the ESC Working Group for Cardiovascular Pharmacotherapy and other prestigious groups. Keynote lectures will be delivered by a distinguished international faculty, while a large number of selected free communications will report new data from basic research laboratories and clinical centers around the globe.
The ICCAD program will include sessions on basic research, stem cell research and myocardial repair, vascular biology and clinical cardiology. We will also dedicate sessions to new advances in pharmacotherapy, especially to the current challenges in antithrombotic and antiplatelet therapy and to the new drugs in lipidology and diabetes which may so dramatically change the outcome and improve the prognosis. We will also discuss the latest news in interventional cardiology, stents and strategies, including the challenge of concomitant carotid and peripheral vascular disease, the rapidly expanding field of valvular interventions, and the role of the heart team and surgical management of coronary and cardiovascular disease.